Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease

Nephron

Volumn 90, Issue 3, 2002, Pages 256-261

  Shibasaki, Yasunobu ^a   Masaki, Hiroya ^a   Nishiue, Takashi ^a   Nishikawa, Mitsushige ^a   Matsubara, Hiroaki ^a   Iwasaka, Toshiji ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin II receptor antagonist; Angiotensin II type 2 receptor; End stage renal disease; Hemodialysis; Left ventricular hypertrophy

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LOSARTAN;

ADULT; AGED; ANGIOTENSIN BLOOD LEVEL; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; UREMIA;

ADULT; AGED; AGED, 80 AND OVER; AMLODIPINE; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENTS; ECHOCARDIOGRAPHY; ENALAPRIL; FEMALE; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; LOSARTAN; MALE; MIDDLE AGED; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; RENAL DIALYSIS;

EID: 0036190829     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000049060     Document Type: Article

References (35)

1. Report of the annual statistical survey of the Japanese Society for Dialysis Therapy in 1996
2. Combined report on regular dialysis and transplantation in Europe
3. Left ventricular hypertrophy in end-stage renal disease
4. Regression of left ventricular hypertrophy on hypertensive dialyzed uremic patients on long-term antihypertensive therapy
5. Pathophysiological role of angiotensin II type 2 receptor in cardiovascular and renal diseases
6. Differential kinetics of circulating angiotensin IV and II after treatment with angiotensin II type 1 receptor antagonist and their plasma levels in patients with chronic renal failure
7. Recommendations regarding quantitation in M-mode echocardiography: Results of survey of echocardiographic measurements
8. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography
9. The reliability and validity of echocardiographic measurement of left ventricular mass index in hemodialysis patients
10. The inferior vena cava diameter as a marker of dry weight in chronic hemodialyzed patients
11. Simultaneous analysis of morbidity and mortality factors in chronic hemodialysis patients
12. Interaction between hypertension and other cardiovascular risk factors in survival of hemodialyzed patients
13. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy
14. Impact of left ventricular hypertrophy on survival in end-stage renal disease
15. Outcome of congestive heart failure, dilated cardiomyopathy, hypertrophic hyperkinetic disease and ischemic heart disease in dialysis patient
16. Prolonged therapy with ACE inhibitors induced a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects
17. The influence of ACE inhibition on myocardial mass and diastolic function in chronic hemodialysis patients with adequate control of blood pressure
18. Effects of losartan on blood pressure and left ventricular mass in essential hypertension
19. Influence of angiotensin II antagonist Valsartan on left ventricular hypertrophy in patients with essential hypertension
20. Losartan in essential hypertension: Effects on blood pressure and left ventricular mass
21. Long-term effects of losartan on blood pressure and left ventricular structure in essential hypertension
22. Increased left ventricular mass after losartan treatment
23. Effects of intravascular volume loading and unloading on atrial sizes and left ventricular function in dialyzed uremic man
24. Role of anemia in pathogenesis of left ventricular hypertrophy in end-stage renal disease
25. Long-term myocardial effects of correction of anemia with recombinant human erythropoietin in aged patients on hemodialysis
26. Risk factors for left ventricular hypertrophy in chronic hemodialysis patients
27. Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients
28. Renin profiling for diagnosis, risk assessment, and treatment of hypertension
29. Relationship between left ventricular hypertrophy and plasma renin activity in chronic hemodialysis patients
30. Rat angiotensin II (type 1A) receptor mRNA regulation and subtype expression in myocardial growth and hypertrophy
31. Mechanical stretch induces enhanced expression of angiotensin II receptor subtypes in neonatal rat cardiac myocytes
32. Angiotension II-forming pathways in normal and failing human hearts
33. Therapy with recombinant human erythropoietin reduced cardiac size and improves heart function in chronic hemodialysis patients
34. Vascular change in hemodialysis patients in response to recombinant human erythropoietin
35. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin